Cambridge, UK, 8 July 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a company driving the application of gene editing and gene modulation within the global life science market, today announced that Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug (IND) application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology. The Phase 1 trial will be the first CAR-…
Artificial Intelligence (AI) and machine learning in healthcare and life sciences holds the promise of reforming the industry. Generating and harnessing mass pools of data, the healthcare and life science industries are particularly primed to profit from the potential of AI, offering the unearthing of hidden insights in a world of unstructured data. Frost and Sullivan predicts that the health AI market, valued at US$600 million in 2014 will reach a high of US$6.2 billion by 2022.
The innovative analytics strategies behind AI and machine learning are increasingly having more impact on all…
AMSBIO reports on the pioneering research published** in a collaborative effort between researchers in the School of Engineering, University of Newcastle and Department of Pharmacology, University of Cambridge, UK that has cited Biotinylated Hyaluronan Binding Protein (biotin-HABP) supplied by the company in its investigation into the cancer resistance of the naked mole-rat (NMR).Hyaluronan (also known as Hyaluronic Acid, or HA) is a glycosaminoglycan with a simple conserved structure. It is widespread in the extracellular matrix, playing many…
Are you attending ON Helix 19? Do you fancy winning one of our wise owls? During the event, if you use our event hashtag (#ONHelix19) you will be automatically entered to win one of our owls!
Terms and ConditionsOne owl to give away on each day.The winner will be chosen at random and must have attended the event.Winner will be contacted by direct message no later 19 July.LinkedIn and Twitter are the elegable social media platforms.
**Please note that the eyes are pins (with backings) so this is not a toy. Best to be used on a desk to spark wise thoughts.**
Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totalling over £8m to develop new antibiotics effective against drug-resistant superbugs and to expand its proprietary machine learning computational platform.
Oxford, UK, 18thJune, 2019– Oxford Drug Design Limited, a biotechnology company with a proprietary computational and machine learning platform, announced today that CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) has agreed to back their lead in-house discovery…
Following the recent announcement of the innovative mentoring initiative, called TechBuddy, run by Eastern AHSN and Cambridge Network to match up technology innovators in the region with people leading work in the NHS, the scheme is looking for applications from new, interested parties.
Bringing together strengths in healthcare and technology holds enormous promise for the nation’s health and wealth. There is still, however, huge scope for better understanding between technology companies and those leading work in the NHS.
The TechBuddy scheme is designed to help bridge this gap between the…
27 June 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.
Dr Haurum has over 20 years’ experience in the international biotech industry. Previously John was Chief Executive Officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies, with multiple strategic collaborations with AbbVie, Merck KGaA, Denali and Boehringer…
CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the…
BioBridge Ltd, the UK-based bioscience innovation consultancy, announces the start of a new working relationship with Osprey Consultants LLC, a US-based animal health consultancy specialising in veterinary medicine product development and commercialisation. BioBridge and Osprey will assist each other in providing services for their respective clients.
Osprey’s founder, Dr. William Symington, has, similar to BioBridge’s Meredith Lloyd-Evans, long-term experience in the animal health industry. His 40 years of experience has covered all domesticated species and all key global regions.…
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a unique transdermal delivery technology, TEPI Patch®, has appointed John Burt as Chief Executive Officer, effective 24 June 2019. Nigel Davis, the current CEO, will remain with the Company as Chief Business Officer.
Medherant has completed two Phase I clinical studies with an Ibuprofen TEPI Patch and is discussing its further development with potential commercial partners whilst it focuses on the development of patch products to treat…